-$0.61 EPS Expected for Neon Therapeutics Inc (NASDAQ:NTGN) This Quarter

Brokerages forecast that Neon Therapeutics Inc (NASDAQ:NTGN) will announce earnings of ($0.61) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Neon Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.46). Neon Therapeutics reported earnings per share of ($0.67) in the same quarter last year, which suggests a positive year over year growth rate of 9%. The firm is scheduled to announce its next quarterly earnings results on Monday, November 11th.

According to Zacks, analysts expect that Neon Therapeutics will report full year earnings of ($2.51) per share for the current financial year, with EPS estimates ranging from ($3.18) to ($1.85). For the next year, analysts forecast that the firm will post earnings of ($2.28) per share, with EPS estimates ranging from ($4.17) to ($1.42). Zacks’ EPS averages are an average based on a survey of research analysts that cover Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.01).

A number of equities analysts recently commented on the company. Mizuho set a $21.00 price objective on Neon Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 30th. Morgan Stanley cut their target price on Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating for the company in a research note on Tuesday, July 16th. Robert W. Baird started coverage on Neon Therapeutics in a research note on Thursday, July 25th. They set an “outperform” rating and a $15.00 target price for the company. ValuEngine raised Neon Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Neon Therapeutics in a research note on Monday, September 16th. Seven analysts have rated the stock with a buy rating, Neon Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $13.00.

Neon Therapeutics stock traded up $0.01 during trading on Friday, reaching $2.20. 78,679 shares of the company were exchanged, compared to its average volume of 249,140. Neon Therapeutics has a 52-week low of $1.61 and a 52-week high of $9.70. The company has a market capitalization of $62.15 million, a P/E ratio of -0.40 and a beta of 1.49. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.13 and a quick ratio of 6.13. The stock’s 50 day simple moving average is $2.31 and its two-hundred day simple moving average is $4.10.

A number of hedge funds have recently bought and sold shares of the business. Morgan Stanley increased its stake in Neon Therapeutics by 10.8% during the second quarter. Morgan Stanley now owns 40,522 shares of the company’s stock worth $192,000 after acquiring an additional 3,939 shares during the last quarter. Vanguard Group Inc. increased its stake in Neon Therapeutics by 3.6% during the second quarter. Vanguard Group Inc. now owns 612,398 shares of the company’s stock worth $2,903,000 after acquiring an additional 21,387 shares during the last quarter. BlackRock Inc. increased its stake in Neon Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock worth $3,631,000 after acquiring an additional 79,729 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in Neon Therapeutics during the second quarter worth $149,000. Finally, Northern Trust Corp increased its stake in Neon Therapeutics by 8.5% during the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock worth $789,000 after acquiring an additional 12,971 shares during the last quarter. 67.10% of the stock is owned by institutional investors.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: Trading Strategy

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.